Brad Canino
Stock Analyst at Guggenheim
(4.77)
# 91
Out of 5,072 analysts
20
Total ratings
76.47%
Success rate
32.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $109.19 | +41.95% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $5.19 | +34.87% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $67.66 | +33.02% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $17.89 | +123.59% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $44.75 | +101.12% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $28.32 | -29.38% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $101.14 | +8.76% | 1 | Sep 22, 2025 | |
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $11.85 | +51.90% | 1 | Sep 4, 2025 | |
| RLAY Relay Therapeutics | Assumes: Buy | $15 | $7.92 | +89.39% | 1 | Sep 4, 2025 | |
| CCCC C4 Therapeutics | Initiates: Buy | $8 | $2.71 | +195.20% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $34.09 | +111.21% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $12.14 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.82 | +109.42% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $450 | $27.46 | +1,538.75% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $26.71 | +105.92% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $44.17 | -32.08% | 2 | Mar 31, 2021 |
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $109.19
Upside: +41.95%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $5.19
Upside: +34.87%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $67.66
Upside: +33.02%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $17.89
Upside: +123.59%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $44.75
Upside: +101.12%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $28.32
Upside: -29.38%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $101.14
Upside: +8.76%
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $11.85
Upside: +51.90%
Relay Therapeutics
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $7.92
Upside: +89.39%
C4 Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.71
Upside: +195.20%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $34.09
Upside: +111.21%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $12.14
Upside: -
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $3.82
Upside: +109.42%
Mar 31, 2021
Initiates: Neutral
Price Target: $450
Current: $27.46
Upside: +1,538.75%
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $26.71
Upside: +105.92%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $44.17
Upside: -32.08%